25 C
Vientiane
Friday, May 30, 2025
spot_img
Home Blog Page 466

Li Ka Shing Foundation and Temasek Trust Jointly Commit S$12 Million to Acquire Systems and Advance Clinical Trial for Innovative Histotripsy Cancer Therapy in Singapore

  • Li Ka Shing Foundation (LKSF) and Temasek Trust (TT) are purchasing and donating two Histotripsy Systems to the National Cancer Centre Singapore (NCCS) and the National University Cancer Institute, Singapore (NCIS) in Singapore to perform clinical trials to study novel ultrasound therapy for liver, kidney and pancreatic cancers.
  • The funding from LKSF and TT will be disbursed through a Donor-Advised Fund managed by TT Foundation Advisors (TTFA), which catalyses additional capital from other donors to support cancer research.

SINGAPORE – Media OutReach Newswire – 04 April 2025 – The Li Ka Shing Foundation (LKSF) and Temasek Trust (TT) have committed S$12 million to bring innovative non-invasive ultrasound-based histotripsy tumour clinical trials to Singapore.

The National Cancer Centre Singapore (NCCS) and the National University Cancer Institute, Singapore (NCIS) will each receive one Histotripsy System – the first of such to be available in Southeast Asia. The funding from LKSF and TT will also support a clinical trial in Singapore for patients with liver, kidney, and pancreatic cancers, advancing regional cancer research and innovation.

Mr. Dickson Lim, Head, TTFA, said, “We at TTFA are delighted to have the Li Ka Shing Foundation and Temasek Trust come together to catalyse this important initiative, to study this innovative non-invasive ultrasound-based cancer therapy in Southeast Asia. We are privileged to work alongside NCCS and NCIS to support clinical research and trials to use this novel modality that targets important cancers. Over time, we aim to attract additional philanthropic capital from other donors to sustainably support the next phase of cancer research.”

Rising Regional Cancer Burden and the Need for Innovative Treatment

Liver, kidney, and pancreatic cancers are on the rise across Asia, with Southeast Asia experiencing the fastest-growing incidence and mortality rates. Factors such as aging populations, changing lifestyles, and environmental exposure contribute to the regional cancer burden. In Singapore, liver cancer is the third most common cause of cancer death for men, with liver and pancreatic cancers among the top 10 causes of cancer mortality. These cancers often do not show symptoms until the later stages, making early detection and effective treatment difficult.

Histotripsy: An Innovative Technology

Developed by US medical company, HistoSonics, the HistoSonics Histotripsy System generates microbubbles that rapidly expand and collapse, producing shock waves that break down tumours at the cellular level. This approach does not require surgery, and can non-invasively destroy tumours, including those that cannot be surgically removed.

Unlike surgery, radiotherapy, or traditional ablation, histotripsy requires no incisions or radiation, offering a painless, scarless, and bloodless treatment.

Clinical Trial on Histotripsy Therapy and Research in Asia

The application for the clinical trial using the HistoSonics Histotripsy System is being prepared. Professor Brian Goh Kim Poh, Head of Hepatopancreatobiliary and Transplant Surgery, NCCS and Singapore General Hospital, and principal investigator of the trial, will work alongside a team of oncologists, interventional radiologists and researchers from both NCCS and NCIS.

Professor Goh said, “We are excited to have the opportunity to embark on clinical trials for liver, kidney and pancreatic cancers which are prevalent in Southeast Asia. We plan to initiate trials for liver cancers first. While surgery and local ablative therapies are the main treatment modalities for liver cancers today, not all patients are suited to undergo these invasive treatments due to various factors such as patient fitness, tumour location or underlying liver disease. For these patients, innovations such as histotripsy offer an alternative option with potential advantages as it is non-invasive. We are extremely grateful to the Li Ka Shing Foundation and Temasek Trust for their generosity and strong support towards advancing cancer research by enabling us to study this novel technology.”

Associate Professor Glenn Kunnath Bonney, Senior Consultant, Division of Surgical Oncology, NCIS, said: “We are currently preparing for the clinical trial of histotripsy as a potential treatment approach for patients with liver and other complex cancers. I have just returned from an international meeting where I was shown the promising results from early clinical trials. This initiative reflects our ongoing commitment to expanding evidence-based options through rigorous research, with the goal of improving patient outcomes over time. We are grateful to the Li Ka Shing Foundation and Temasek Trust for their support, and look forward to working with our partners to build the necessary foundation for careful clinical studies.”

The clinical trial is slated to commence later this year, with a targeted enrolment of 40 patients who meet the trial criteria and are reviewed by a multi-disciplinary team.

Ensuring Sustainable Impact through Strategic Philanthropy

To drive long-term impact in the region, the funding from LKSF and TT will be disbursed through a Donor-Advised Fund (DAF) managed by TTFA, the philanthropy advisory services arm of TT. Through the DAF, TTFA aims to attract additional capital from other donors over time to sustainably support the next phase of cancer research.

Hashtag: #LiKaShingFoundation #TemasekTrust

The issuer is solely responsible for the content of this announcement.

About Li Ka Shing Foundation

Li Ka Shing Foundation believes in philanthropy with societal impact. Since 1980, we have been helping to reform education and further medical research. To date, Mr Li Ka-shing has invested over HK$30 billion in projects covering education, medical services, charity and anti-poverty programmes, with about 80% of the projects in Mainland China and Hong Kong.

About Temasek Trust

Temasek Trust was established by Temasek Holdings and is a steward of philanthropic assets. It aims to catalyse positive impact by protecting the planet, uplifting communities, connecting people, and advancing capabilities. By forging new pathways for philanthropy and impact investing with like-minded partners, Temasek Trust seeks to promote catalytic philanthropy as a force for good. For more information, visit . Follow us on , , , and .

About TT Foundation Advisors (TTFA)

TT Foundation Advisors is an independent professional philanthropy services advisory arm of Temasek Trust. It provides specialised philanthropy advisory and management services to philanthropic foundations, family offices, business corporations, philanthropists, and charities. It taps on Temasek Trust’s insights, capabilities, and resources, as well as the expertise and evidence-based interventions across the wider philanthropic ecosystem, to deliver strategic and impactful solutions for its clients.

About National Cancer Centre Singapore (NCCS)

The National Cancer Centre Singapore (NCCS) is a leading national and regional tertiary cancer centre with specialists who are experts in treating cancer. In addition to offering holistic and multidisciplinary oncology care, our clinicians and scientists collaborate with local and international partners to conduct robust, cutting-edge clinical and translational research. To achieve its vision of being a global leading cancer centre, NCCS offers world-class care and shares its depth of experience and expertise by training local and overseas medical professionals.

To meet growing healthcare needs, the new NCCS building opened in 2023 with increased capacity and expanded facilities dedicated to cancer care, rehabilitation, research and education. To give patients the best treatment outcomes, advanced and innovative treatment such as proton therapy is offered at the new Goh Cheng Liang Proton Therapy Centre at NCCS. For more information, please visit

About National University Cancer Institute, Singapore (NCIS)

The National University Cancer Institute, Singapore (NCIS) is an academic, national specialist centre for cancer under the National University Health System (NUHS), and is the only public cancer centre in Singapore that treats both paediatric and adult cancers in one facility.

As one of two national cancer centres in Singapore, NCIS (pronounced as “n-sis”) offers a broad spectrum of cancer care and management from screening, diagnosis and treatment to rehabilitation and survivorship, as well as palliative and long-term care. NCIS’ strength lies in the multidisciplinary approach taken by our clinician scientists and clinician-investigators to develop a comprehensive and personalised plan for each cancer patient.

NCIS provides the full suite of specialised oncology and haematology services at the NUH Medical Centre at Kent Ridge, Singapore, including those by the NCIS Chemotherapy Centre, NCIS Radiotherapy Centre and NCIS Cellular Therapy Centre.

NCIS also offers cancer services at other hospitals in Singapore:
* NCIS Cancer & Blood Clinic @ Ng Teng Fong General Hospital
* NCIS Radiotherapy Centre @ Tan Tock Seng Hospital
* NCIS Radiotherapy Clinic @ Khoo Teck Puat Hospital

To bring cancer care even closer to our patients, our NCIS on the Go programme delivers a range of cancer services at clinics within the community for their convenience. For more information, please visit .

About HistoSonics

HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumours. The company is currently focused on commercialising their HistoSonics Histotripsy System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, brain, and others. HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Minnesota.

For more information on the HistoSonics Histotripsy System, please visit: . For patient related information, please visit: .

Easter and School Holiday Escapes, A Family-Friendly Retreat at Sheraton Bali Kuta Resort

BALI, Indonesia, April 4, 2025 /PRNewswire/ — Celebrate Easter and the upcoming school holidays with an unforgettable beachfront getaway at Sheraton Bali Kuta Resort. With a refreshed lobby, a vibrant social lounge at &More by Sheraton, and the newly renovated “PlayHouse” kids club, the resort blends premium comfort with family-friendly fun in the heart of Kuta.

Junior Family Suite at Sheraton Bali Kuta, featuring two separate sleeping areas for comfort and privacy. Parents can unwind in their private king-bedroom, while kids enjoy their sofa bed and fold-out chair—all within a spacious 62 sqm suite.
Junior Family Suite at Sheraton Bali Kuta, featuring two separate sleeping areas for comfort and privacy. Parents can unwind in their private king-bedroom, while kids enjoy their sofa bed and fold-out chair—all within a spacious 62 sqm suite.

Wake up to the gentle sound of waves and breathtaking ocean views from your private balcony, setting the perfect tone for a memorable family escape. The Suite Experience package offers spacious comfort with a sofa bed, kids’ tent amenities, a one-time minibar, VIP perks, and a special family room setup. Begin your day with a lavish buffet breakfast, fueling adventures for the little ones at PlayHouse, where 20+ activities keep them entertained, while parents unwind by the infinity pool or enjoy curated moments with the Side by Side program. Afternoons invite relaxation and indulgence with the Jewelry Box Afternoon Tea, a delightful treat for the whole family. Families can also enjoy 15% off dining, including the famous Sunday Social Brunch, where kids dine free. As the sun sets, the revitalized lobby offers a warm, inviting space for coffee, pastries, and social gatherings, while &More by Sheraton sets the scene for a perfect evening with live music, handcrafted cocktails, and stunning views of Kuta Beach. Savor authentic Italian cuisine at Bene Italian Kitchen, sip signature drinks at &More by Sheraton, or explore diverse culinary delights at Daily Social, all with panoramic ocean vistas. Just steps from Beachwalk Shopping Center, local markets, and the iconic WXYZ Bar at Aloft Bali Kuta, the resort offers the perfect balance of relaxation and excitement. Whether an Easter egg hunt by the beach or a sunset cocktail, every moment is designed for lasting memories. Ashley Lai, Cluster General Manager of Sheraton Bali Kuta Resort & Aloft Bali Kuta at Beachwalk, shares “It’s more than a place to stay, it’s a destination. With refreshed spaces, family-friendly experiences, and unmatched dining, we create moments that last a lifetime.” Enjoy the Marriott Bonvoy Fast Track program, become a member and register by April 14, 2025, to earn 1,000 bonus points and 1 Elite Night Credit per night. For more information visit Sheraton Bali Kuta Resort.

South Korea Court Upholds President Yoon’s Impeachment, Strips Him of Office

Yoon Suk Yeol
Badges and flags are displayed on a table for supporters of South Korea president Yoon Suk Yeol and former president Park Geun-hye, as they gather prior to the announcement of the Constitutional Court's verdict on Yoon's impeachment outside the presidential residence in Seoul on April 4, 2025. (Photo by ANTHONY WALLACE / AFP)

By Hieun Shin and Claire Lee/AFP – South Korea’s Constitutional Court on 4 April upheld President Yoon Suk Yeol’s impeachment over his disastrous martial law declaration, voting unanimously to strip him of office for violating the constitution.

Vientiane Province Steps Up Wildfire Prevention Efforts as Fire Alerts Increase

Phou Phanang National Biodiversity Conservation Area Wildfire (Photo: Somchith Phanthouamath)

Vientiane Province has recorded 385 fire alerts in the first quarter of 2025, signaling an increase in fire activity, according to Global Forest Watch.

NUS researchers combine 3D bioprinting with AI to personalise oral soft tissue grafts

Artificial intelligence streamlines the optimisation of bioprinting parameters for oral soft tissue grafts, reducing time and resource demands while enabling efficient, personalised dental treatments

SINGAPORE, April 4, 2025 /PRNewswire/ — A team of researchers from the National University of Singapore (NUS) has developed a method to fabricate personalised gingival (gum) tissue grafts using an innovative combination of 3D bioprinting and artificial intelligence (AI).

Led by Assistant Professor Gopu Sriram from NUS Faculty of Dentistry, the team’s approach presents a more customisable and less invasive alternative to traditional grafting methods, which often involve harvesting tissue from the patient’s mouth — a process that can be both uncomfortable and constrained by the availability of suitable tissue.

The 3D bioprinting and AI-enabled technique has the potential to address key challenges in dental procedures more effectively, such as repairing gum defects caused by periodontal disease or complications from dental implants. For instance, by enabling the precise fabrication of tissue constructs tailored to individual patients, the method can significantly improve treatment outcomes, reduce patient discomfort, and minimise the risk of complications, such as infections, during recovery.

The team’s research was published in the journal Advanced Healthcare Materials on 17 December 2024, and was supported by grants from National Additive Manufacturing Innovation Cluster (NAMIC) and National University Health System (NUHS).

Turbocharging the bioprinting process with AI

Gum tissue grafts are essential in dental care, particularly for addressing mucogingival defects such as gum recession, and complications arising from periodontal disease or dental implants. Typically, these grafts are harvested from the patient’s mouth. Though effective, these procedures come with significant drawbacks: patient discomfort, limited tissue availability, and a higher risk of postoperative complications.

To overcome these challenges, the researchers turned to 3D bioprinting, a technique that fabricates custom-made tissue grafts tailored to the specific dimensions of each patient’s defect. They developed a specialised bio-ink which supports the growth of healthy cells, while also ensuring the material can be printed accurately and holds its shape and structure.

However, the viability of 3D bioprinting is only as good as the parameters applied during the process. Factors such as extrusion pressure, print speed, nozzle dimensions, bio-ink viscosity and printhead temperature all play a crucial role in determining the final properties and performance of the printed component. Tuning these parameters has traditionally been done through tedious, manual trial-and-error experiments that are extremely time- and resource-consuming.

“To speed up the 3D bioprinting process, we integrated AI into our workflow to address this critical bottleneck,” said Professor Dean Ho, Head of the Department of Biomedical Engineering in the College of Design and Engineering at NUS, and co-corresponding author of the research paper. “This approach greatly streamlines the process by reducing the number of experiments needed to optimise the bioprinting parameters — from potentially thousands to just 25 combinations,” added Prof Ho, who is also Director of the Institute for Digital Medicine (WisDM) at NUS Yong Loo Lin School of Medicine, and N.1 Institute for Health (N.1) at NUS.

This tremendous efficiency boost afforded by the team’s AI-driven workflow saves time and resources while ensuring the creation of tissue constructs with precise dimensions and structural integrity.

“Our study is among the first to specifically integrate 3D bioprinting and AI technologies for the biofabrication of customised oral soft tissue constructs,” said Asst Prof Sriram, who is also the Thrust Co-Lead of Dental and Craniofacial 3DP Applications at NUS Centre for Additive Manufacturing (AM.NUS). “3D bioprinting is by far more challenging than conventional 3D printing because it involves living cells, which introduce a host of complexities to the printing process.”

The bioprinted gum tissue grafts exhibited strong biomimetic properties, maintaining over 90% cell viability immediately after printing and throughout an 18-day culture period. The grafts also retained their shape and structural integrity, while histological analyses confirmed the presence of key proteins and a multi-layered structure closely resembling natural gum tissue.

The future of dental care

In dentistry, the ability to produce personalised gum tissue grafts with improved efficiency, structural integrity, and biomimetic properties could address longstanding clinical challenges associated with periodontal diseases and dental implants. “This research demonstrates how AI and 3D bioprinting can converge to solve complex medical problems through precision medicine,” added Asst Prof Sriram. “By optimising tissue grafts for individual patients, we can reduce the invasiveness of dental procedures while ensuring better healing and recovery.”

Excitingly, the potential implications of this research extend beyond dentistry. “3D bioprinting allows us to create tissue grafts that precisely match the dimensions of a patient’s wounds, potentially reducing or eliminating the need to harvest tissue from the patient’s body,” said Asst Prof Sriram.

“This level of customisation minimises graft distortion and tension during wound closure, reducing the risk of complications, surgery time and discomfort to the patients.” said Dr Jacob Chew, a periodontist, co-investigator of the study, and Academic Fellow at NUS Faculty of Dentistry.

Furthermore, the scarless healing characteristics of oral tissue provide a unique advantage, as insights from this study could inform the fabrication of similar grafts for other barrier tissues, such as skin, potentially aiding in the scarless healing of skin wounds.

Future research will focus on translating these findings from bench to bedside. The team plans to conduct in vivo studies to assess the integration and stability of the grafts in oral environments. They also aim to explore the integration of blood vessels into the grafts through multi-material bioprinting to create more complex and functional constructs. With these developments, the researchers hope to advance the field of regenerative dentistry while paving the way for broader applications in tissue engineering.

Read more at: https://news.nus.edu.sg/combining-3d-bioprinting-with-ai-to-personalise-oral-soft-tissue-grafts.  

NeuralFin adds strategic investors, DLH accelerates AI Agent push

HONG KONG SAR – Media OutReach Newswire – 04 April 2025 – DL Holdings Group, a company listed on the Hong Kong Stock Exchange Main Board (stock code: 1709.HK) announced the strategic restructuring of DL Digital Family Office (DLDFO). In this transaction, DLDFO introduced three new strategic investors at a valuation of $35 million and launched an employee stock ownership plan (ESOP) to bolster the technological R&D and market expansion of its wholly-owned subsidiary, NeuralFin, in the AI Agent sector.

NeuralFin has pioneered the integration of neuroscience and artificial intelligence, transforming AI Agents from passive responders to proactive service providers. In practical applications, NeuralFin’s AI Agents have developed multiple specialized service modules. The Intelligent Investment Advisor Agent offers 24/7 asset allocation services, while the Behavioral Prediction Agent leverages behavioral economics and neuroscience to build investor behavior models, effectively identifying and warning against irrational trading tendencies.

“Traditional fintech only addresses expressed client needs, but our AI Agents can uncover unspoken demands, truly achieving ‘autonomous learning and service during sleep,'” said Andy Chen, Chairman and CEO of DL Holdings. “NeuralFin’s AI Agent system is redefining the standards and experience of wealth management services.”

Regarding strategic investments, DL Holdings transferred 28% equity of DLDFO to three professional investment institutions at a price of $9.8 million. This round of financing reflects a 15% valuation increase compared to the previous round, underscoring market confidence in NeuralFin.

The newly introduced investors are industry leaders in their respective sectors. GPTX Tech-Driven LPF, a Hong Kong-based tech investment firm, specializes in AI and digital technologies and will enhance NeuralFin’s technical upgrades with its robust AI algorithm expertise. C Capital AI Limited, part of the asset management platform under Youngtimers AG (a Swiss-listed company), brings extensive industry connections and investment experience, having backed projects like XPeng Motors and Lalamove. Shuren Education Limited, a key player in education, will drive innovative applications of NeuralFin in the education sector.

For talent retention, DL Holdings launched an ESOP, transferring 25% of DLDFO’s equity to an ESOP platform free of charge, covering executives and core technical teams. This move highlights DL Holdings’ commitment to retaining top talent amid fierce competition in fintech.

Andy Chen stated, “The core competitiveness of tech finance lies in talent. This plan allows our team to directly share in the company’s growth, fostering innovation and cohesion. We look forward to more employees becoming long-term partners as we advance together.”

Moving forward, DL Holdings will deepen its exploration of AI-driven fintech, leveraging the synergy of “technology + capital + talent” to enhance NeuralFin’s service capabilities and market share. The group aims to sustain a virtuous cycle of innovation and commercialization, delivering greater value to investors and leading the next wave of intelligent financial services.

Hashtag: #DLHoldingsGroup

The issuer is solely responsible for the content of this announcement.

indent and Red Seven Announce Strategic Partnership to Strengthen Creative IP-Works

  • This collaboration will leverage Nola’s Creative Writing Platform to enhance webtoon development and drive innovation in IP creation.

TOKYO, April 4, 2025 /PRNewswire/ — indent, Inc., the developer of Nola, a creative Writing platform[*1] that connects over 500,000 writers with more than 30 publishing labels, has entered into a strategic partnership with Red Seven Inc., led by CEO Lee Hyun-seok, a group company of Red Ice Studio, known for producing “Tomb Raider King”.tom

On March 1, 2025, both companies agreed to strengthen the corporate “IP Development Total Package,” leveraging Nola’s extensive database of over 2 million Japanese “gensaku” – original IP-works –  by Providing comprehensive support for businesses, from sourcing and discovering original IP-works to developing them into full-fledged multimedia content, including webtoons, comics, and novels.

indent and Red Seven Announce Strategic Partnership to Strengthen Creative IP-Works
indent and Red Seven Announce Strategic Partnership to Strengthen Creative IP-Works

Purpose of the Partnership

This alliance aims to contribute to the growth and revitalization of the global webtoon market, with a particular focus on Japan and South Korea. It does so by leveraging Red Seven’s production expertise, which has resulted in numerous high-quality global hit webtoons such as “The Great Mage Who Returned After 4000 Years” and “Tomb Raider King”, along with Nola – Creative Writing Platform, indent’s creative platform that connects writers and companies. 

Background and Vision of the Partnership

With the widespread adoption of digital devices, the webtoon market has firmly established itself in South Korea as a platform optimized for multimedia storytelling. This market is experiencing rapid global expansion, including in Japan, and is projected to reach 3.85 trillion yen by 2028[*2]. However, as the industry grows at an unprecedented pace, ensuring a sustainable production system and maintaining quality remain pressing challenges.

Until now, indent has supported businesses seeking to develop media-mixable IPs originating from novels, manga, and webtoons through its IP Development Total Package, leveraging a database of over 2 million Japanese “gensaku” (original IP-works) created by 500,000 writers. With this new partnership, Red Seven will take the lead in overseeing and providing comprehensive support for the webtoon sector within this package.

By utilizing Red Seven’s specialized expertise in establishing and expanding production systems, this collaboration will drive business growth for participating companies while also helping to build a sustainable ecosystem for the long-term success and innovation of the webtoon industry.

Statements from Company Representatives

Red Seven Inc, CEO ,  Lee Hyun-seok
Red Seven Inc, CEO , Lee Hyun-seok

Red Seven Inc, CEO,  Lee Hyun-seok

“As of 2024, Japan’s manga industry has reached a historic high, surpassing 700 billion yen. In light of this industry milestone, Red Seven and indent have formed a business alliance to foster meaningful collaboration in the webtoon market.

Amid this period of growth driven by digital innovation, both our companies recognize the critical importance of developing high-quality IP and productions and are committed to ensuring the sustainable development of the webtoon industry.

Our partnership aims to discover talented creators and nurture original works that captivate both Japanese and global audiences. Both companies will work to create an environment where creators can fully realize their potential.

By combining indent’s expertise in operating Nola – Creative Writing Platform with Red Seven’s extensive experience in webtoon production, this collaboration will enable a mutually complementary partnership. Through these efforts, both our companies seek to contribute to the healthy growth of the webtoon industry and deliver valuable content to readers worldwide.”

indent, Inc., CEO Yuki Kamagata
indent, Inc., CEO Yuki Kamagata

indent, Inc., CEO Yuki Kamagata

“This alliance is a major step toward creating new value in the rapidly expanding webtoon market by maximizing the strengths of both companies.

With demand for Japanese original works increasing around the world, our company envisions to contribute to the development of the industry as a whole by establishing a consistent support system for the creation of media-mixable IP starting from webtoons through this alliance.

indent, Inc. will combine the expertise and resources of both companies to explore new possibilities for webtoon. The goal is to create an environment where writers using the Nola – Creative Writing Platform can focus more on their craft, while also fostering a dynamic ecosystem where businesses and emerging talent connect, leading to the creation of inspiring content.

What is  “IP Development Total Package”?

Target Audience: Companies aiming to create media-mixable IP, starting from webtoons, novels, and manga.
Package Contents: Comprehensive support is provided, covering everything from identifying and acquiring original works to full-scale production.

Recruitment of Japanese “gensaku” (original IP works)

Example: Utilizing the “Editorial Board” Feature

A corporate-exclusive feature within Nola – Creative Writing Platform Novel, a novel submission site where works written on Nola – Creative Writing Platform can be posted directly. This function allows companies to list the types of works they seek and specify key criteria, enabling them to identify and acquire submissions from writers tailored to their needs.

Example: Japanese “gensaku” (original IP works) identify and acquire Contest

Taking advantage of the fact that more than 60,000 new works are created each month on Nola – Creative Writing Platform, the contest facilitates connections between companies and emerging authors. Companies receive support in designing contest requirements to align with the type of works they seek.

Comprehensive assistance is provided for all aspects of contest operations, including contest page design and development, management, and expanding awareness among writers.

Discovery of Japanese “gensaku” (original IP works)

Red Seven, which has produced multiple global hit webtoons, and Yui Tsutsumi, the outside director of indent, recognized for discovering and editing numerous successful works in the isekai (otherworldly) genre, lead IP discovery efforts. A specialized discovery team with expertise in content selection, along with proprietary systems, is used to identify promising original works.

Co-production of works

In the webtoon sector, support is provided for the adaptation of promising Japanese “gensaku” (original works) into webtoons. This process maximizes Indent’s editorial resources while leveraging Red Seven’s expertise and production know-how.

Please feel free to contact us at the following link.
For inquiries, please contact: https://indent.co.jp/en/contact

(*1) What is “Nola – Creative Writing Platform”?

Nola – Creative Writing Platform is a creative platform operated by indent, Inc., that connects authors and companies, with over 500,000 registered authors. In addition to supporting data synchronization across both PC and mobile devices, the platform offers various tools to facilitate structured storytelling, including plot creation, character management, and setting material organization. Features such as manuscript writing, setting management, and plotting functions have been developed to support authors in their creative endeavors.

Nola – Creative Writing Platform Service HP:
https://nola-novel.com/ 

App Store:
https://apps.apple.com/jp/app/id1468307521

Google Play:
https://play.google.com/store/apps/details?id=com.nola.app&hl=ja&gl=US 

(*2) QYResearch <2023> “Global Webtoon Market Report 2023-2029”.

Red Seven Co.

Company name: Red Seven Co.
Location: Victoria Center 7F, 4-6-10 Yotsuya, Shinjuku-ku, Tokyo
CEO: Lee Hyun-seok
Establishment: January 11, 2019 (Established on September 14, 2020 by reorganizing L7, a limited liability company)
Business: Production, import, export and distribution of comics, etc., and production, import, export and distribution of animation and movies, etc.
Company URL: https://redseven.jp/  

indent, inc. Company Profile

Company name: indent, Inc.
Location: 4F Kanda Misaki-cho Building, 3-6-12 Kanda Misaki-cho, Chiyoda-ku, Tokyo
CEO Yuki Kamagata
Establishment: October 8, 2019
Business: Planning, development, and operation of Internet services
Company URL: https://indent.co.jp/en   

OH!SOME Opens its First Store in Vietnam : A One-stop Destination for Global Selected Products


HO CHI MINH, VIETNAM – Media OutReach Newswire – 4 April 2025 – On April 4, 2025, OH!SOME officially enters the Vietnam market, with its very first store opening at Crescent Mall in Ho Chi Minh City.

OH!SOME
OH!SOME

OH!SOME, as a one-stop trendy retail brand, benefits from primary business focus on fashion retail, IP, advanced technology and expanding into diverse family entertainment centers, powered by and efficient global supply chain and a wide selection of high-quality items at competitive prices. The brand values and appreciates local cultures, continuously innovating with new retail concepts and adapting product selections and marketing strategies to align with local tastes and to foster deeper connections.

OH!SOME offers an extensive range of products to ensure customers have plenty of choices tailored to their needs, including beauty and skincare from Korea, food and beverage, daily essentials, electronic goods, fashion toys from around the world. With eye-catching decor, gachapon machines, claw machines and vibrant photo check-in spots in stores, it aims to offer a seamless shopping experience.

The brand works closely with Disney on IP collections. The latest collaborative products featuring classic character Winnie the Pooh are currently available in Crecent Mall OH!SOME store. With exclusive offerings that include plush toys, accessories, picnic mats, outdoor accessories, bento boxes, and plush bags, customers can shop according to their preferences.

In addition, by following OH!SOME’s official accounts @ohsome.vn on Instagram, customers are welcome to join OH!SOME membership to foster customer engagement, enjoy privileges on Meet and Greet events, community gatherings, birthday treats and special deals and promotions through rewarding programs.

OH!SOME had launched 110 stores across countries by the end of March. OH!SOME values Vietnam as a priority market. To strengthen its presence and immense growth potential, OH!SOME’s first store in Hanoi will open in early April and it will expand into more unique stores in other Vietnam major cities. By the end of the first half of 2025, OH!SOME will open up to 8 stores in Vietnam.

Store Address: BF1-02B Floor B1, Crescent Mall, Ton Dat Tien Avenue, Tan Phu Ward, District 7, Ho Chi Minh City.

For more information, follow OH!SOME’s official Instagram: @ohsome.vn.

Hashtag: #OH!SOME

The issuer is solely responsible for the content of this announcement.